Biotechnology startup Ventus Therapeutics is licensing its lead research program, a drug candidate for inflammatory disorders, to Novo Nordisk in exchange for $70 million.
The experimental drug, dubbed VENT-01, is a small molecule that targets inflammasomes, which are protein complexes in immune system cells that activate inflammatory responses.
Though it was a difficult decision to part with Ventus’ lead program, company CEO Marcelo Bigal said the turbulent stock market contributed to the decision to partner with Novo.
“Without Novo, we were funded to bring three programs to the clinic, but with Novo we’re now funded to bring the programs into Phase 2, which means we’re funded into 2025,” Bigal said in an interview.
An inflammasome known as NLRP3 is the focus of Ventus’ experimental treatment. NLRP3 is implicated in a wide range of diseases including Alzheimer’s, Parkinson’s, Type 2 diabetes, intestinal cancer and fatty liver disorders.
Novo will develop VENT-01 for use in nonalcoholic steatohepatitis, chronic kidney disease and other cardiometabolic disorders — areas in which the Danish drugmaker has experience developing medicines. READ MORE
by Gwendolyn Wu
Source: biopharmadive.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
